Citius Pharmaceuticals(CTXR)
$0.52-0.01 (-1.71%)
CTXR
Citius Pharmaceuticals financials statements
$0.52
At close:-0.01 (-1.71%)
Want to see CTXR full AI Analyst Report?
Citius Pharmaceuticals (CTXR) Ratios
1,811 Followers
Citius Pharmaceuticals Ratios
CTXR's free cash flow for Q3 2026 was $-8.68M. For the 2026 fiscal year, CTXR's free cash flow was increased by $0.00 and operating cash flow was $-8.68M. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Dec 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.62 | 0.40 | 5.95 | 9.84 | 18.28 |
| Quick Ratio | 0.13 | 0.17 | 5.95 | 9.84 | 18.28 |
| Cash Ratio | 0.09 | 0.09 | 4.58 | 9.21 | 17.60 |
| Solvency Ratio | -0.70 | -0.91 | -2.66 | -3.16 | -2.38 |
| Operating Cash Flow Ratio | -0.59 | -0.79 | -5.03 | -6.26 | -6.09 |
| Short-Term Operating Cash Flow Coverage | -26.55 | -116.75 | -133.07 | -143.97 | -136.82 |
| Net Current Asset Value | $ -25.48M | $ -28.33M | $ 22.19M | $ 33.99M | $ 63.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.03 | 0.00 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.03 | 0.00 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.94 | 1.66 | 1.14 | 1.11 | 1.08 |
| Debt Service Coverage Ratio | -30.97 | -162.35 | -148.13 | -74.63 | -121.65 |
| Interest Coverage Ratio | -143.87 | 0.00 | 0.00 | -132.52 | -2171.04 |
| Debt to Market Cap | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.19 | 0.02 | 0.05 | 0.10 | 0.12 |
| Net Debt to EBITDA | 0.06 | 0.08 | 0.82 | 1.25 | 3.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 96.77% | 100.74% | 101.80% | 101.74% | 100.31% |
| EBT Per EBIT | 100.41% | 92.51% | 87.03% | 99.25% | 97.97% |
| Return on Assets (ROA) | -28.59% | -33.55% | -31.41% | -29.51% | -16.24% |
| Return on Equity (ROE) | -55.42% | -55.85% | -35.83% | -32.72% | -17.49% |
| Return on Capital Employed (ROCE) | -44.79% | -51.95% | -37.55% | -30.43% | -17.00% |
| Return on Invested Capital (ROIC) | -44.23% | -51.64% | -37.38% | -30.33% | -16.95% |
| Return on Tangible Assets | -130.02% | -269.83% | -93.34% | -74.34% | -31.39% |
| Earnings Yield | -272.82% | -26.97% | -19.52% | -11.42% | -6.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.04 | 0.07 | 0.15 | 0.13 |
| Inventory Turnover | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 14639.18 | 5818.72 | -5498.66 | -2367.38 | -2827.35 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 37968.00 | 14398.57 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 23328.81 | 8579.86 | 5498.66 | 2367.38 | 2827.35 |
| Operating Cycle | 37968.00 | 14398.57 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.40 | -2.43 | -2.98 | -2.91 | -3.35 |
| Free Cash Flow Per Share | -2.40 | -2.43 | -2.98 | -2.91 | -8.88 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.61 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.61 |
| Operating Cash Flow Coverage Ratio | -14.64 | -107.28 | -60.39 | -41.82 | -28.35 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -193.52% | -19.43% | -17.43% | -9.63% | -17.49% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.37 | -3.71 | -5.12 | -8.76 | -15.89 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.20 | 2.07 | 1.84 | 2.87 | 2.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.52 | -5.15 | -5.74 | -10.39 | -5.72 |
| Price-to-Operating Cash Flow Ratio | -0.52 | -5.15 | -5.74 | -10.39 | -15.15 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.52 | 1.55 | -4.12 | -0.01 |
| Enterprise Value Multiple | -0.30 | -3.68 | -4.43 | -7.71 | -13.03 |
| Enterprise Value | 11.28M | 142.12M | 140.68M | 253.57M | 298.21M |
| EV to EBITDA | -0.30 | -3.68 | -4.43 | -7.71 | -13.03 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.42 | -5.04 | -4.84 | -8.94 | -4.64 |
| EV to Operating Cash Flow | -0.42 | -5.04 | -4.84 | -8.94 | -12.30 |
| Tangible Book Value Per Share | -2.22 | -2.42 | 2.33 | 3.56 | 8.84 |
| Shareholders’ Equity Per Share | 6.10 | 6.05 | 9.32 | 10.56 | 18.26 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | -0.01 | -0.02 | -0.02 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -3.38 | -3.38 | -3.34 | -3.45 | -3.19 |
| Tax Burden | 0.97 | 1.01 | 1.02 | 1.02 | 1.00 |
| Interest Burden | 1.01 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.67 | 0.72 | 0.89 | 0.84 | 1.05 |
Currency in USD

